Ragna Lohmann

Statistics

Publications

Citations

H-Index

Active since

2017

Affiliations

Ragna Lohmann is an author at Boehringer Ingelheim (Germany) specializing in pharmacokinetic study design, bioequivalence assessment, and pharmacokinetics of monoclonal antibodies.

Publications per year

2017–2021

Publications

A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

Willem Hettema, Christopher Wynne, Benjamin Lang et al. · Expert Opinion on Investigational Drugs · 2017 · 29 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC

Edward S. Kim, Sigrid Balser, Klaus Röhr et al. · JTO Clinical and Research Reports · 2021 · 10 citations · Full text

Medicine, Oncology, Pharmacology +10

1–2 of 2